Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6091 to 6105 of 8314 results

  1. NICE recommends that a new model for multiple sclerosis is developed, ideally based on UK patient cohorts, which uses the best available evidence (including experience to date from the risk-sharing scheme) and includes all currently available treatments.

    Recommendation ID TA254/2 Question NICE recommends that a new model for multiple sclerosis is developed, ideally based on UK patient cohorts

    Research recommendation
    Published
    9 June 2015

  2. NICE recommends that further research directly comparing the clinical and cost effectiveness of ranibizumab and bevacizumab in people with diabetic macular oedema should be conducted.

    Recommendation ID TA274/1 Question NICE recommends that further research directly comparing the clinical and cost effectiveness of ranibizumab

    Research recommendation
    Published
    9 June 2015

  3. NICE recommends that future trials should include longer-term follow-up, beyond the initial hospital episode, with a view to informing the cost-effectiveness modelling and reducing uncertainty.

    Recommendation ID DG13/4 Question NICE recommends that future trials should include longer-term follow-up, beyond the initial hospital

    Research recommendation
    Published
    9 June 2015

  4. NICE recommends that health economic models are developed to capture the impact of interventions on short-term outcomes such as hypoglycaemia. In addition, the feasibility of incorporating more recently developed risk prediction models for cardiovascular disease such as QRisk2 and observational data from registries such as the Swedish National Diabetes Register into health economic models for type 1 diabetes should be explored.

    Recommendation ID DG21/3 Question NICE recommends that health economic models are developed to capture the impact of interventions on short-term

    Research recommendation
    Published
    11 April 2016

  5. NICE recommends that research should be carried out to directly compare eltrombopag with non-thrombopoietin receptor agonist treatments routinely used in UK clinical practice.

    Recommendation ID TA293/1 Question NICE recommends that research should be carried out to directly compare eltrombopag with non-thrombopoietin

    Research recommendation
    Published
    9 June 2015

  6. NICE recommends that robust evidence be generated to show the clinical effectiveness of pharmacokinetic dose adjustment of continuous infusion 5-FU in people with colorectal cancer.

    Recommendation ID DG16/2 Question NICE recommends that robust evidence be generated to show the clinical effectiveness of pharmacokinetic

    Research recommendation
    Published
    9 June 2015

  7. NICE recommends that studies directly comparing different epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation test methods are performed. These studies should include the re-testing of stored non-small-cell lung cancer (NSCLC) tumour samples using different EGFR-TK mutation test methods and should link to patient outcomes.

    Recommendation ID DG9/1 Question NICE recommends that studies directly comparing different epidermal growth factor receptor tyrosine kinase

    Research recommendation
    Published
    9 June 2015

  8. NICE recommends the development of patient registries for multiple sclerosis to capture long-term treatment-related outcomes.

    Recommendation ID TA254/1 Question NICE recommends the development of patient registries for multiple sclerosis to capture long-term treatment-related

    Research recommendation
    Published
    9 June 2015

  9. NICE recommends the use of eculizumab for atypical haemolytic uraemic syndrome (aHUS) only if all the following arrangements are in place: - coordination of eculizumab use through an expert centre - monitoring systems to record the number of people with a diagnosis of atypical - haemolytic uraemic syndrome and the number who have eculizumab, and the dose and duration of treatment - a national protocol for starting and stopping eculizumab for clinical reasons - a research programme with robust methods to evaluate when stopping treatment or dose adjustment might occur.

    Recommendation ID HST1/1 Question NICE recommends the use of eculizumab for atypical haemolytic uraemic syndrome (aHUS) only if all the

    Research recommendation
    Published
    9 June 2015

  10. NICE supports the manufacturer's ongoing commitment to collect data on the effectiveness of enzalutamide after previous treatment with abiraterone.

    Recommendation ID TA316/1 Question NICE supports the manufacturer's ongoing commitment to collect data on the effectiveness of enzalutamide

    Research recommendation
    Published
    9 June 2015

  11. Noisy respiratory secretions:- In people considered to be in the last few hours and days of life, are antisecretory anti-muscarinic drugs (used alongside nursing interventions, such as repositioning and oropharyngeal suction) better at reducing noisy respiratory secretions and patient, family and carer distress without causing unwanted side effects, than nursing interventions alone?

    Recommendation ID NG31/3 Question Noisy respiratory secretions:- In people considered to be in the last few hours and days of life, are

    Research recommendation
    Published
    27 January 2016

  12. Non-invasive tests for diagnosing NAFLD and advanced liver fibrosis in children and young people:- Which non-invasive tests most accurately diagnose NAFLD and advanced liver fibrosis in children and young people?

    Recommendation ID NG49/3 Question Non-invasive tests for diagnosing NAFLD and advanced liver fibrosis in children and young people:- Which

    Research recommendation
    Published
    24 August 2016

  13. Recommendation 4 Weight management programmes. Who should take action? Research councils, commissioners and funders. Researchers and investigators.

    Recommendation ID PH47/4 Question Recommendation 4 Weight management programmes. Who should take action? Research councils, commissioners

    Research recommendation
    Published
    9 June 2015

  14. Red blood cell transfusion thresholds for patients with chronic cardiovascular  disease:- What is the clinical and cost effectiveness of restrictive compared with liberal red blood cell thresholds and targets for patients with chronic cardiovascular disease?

    Recommendation ID NG24/1 Question Red blood cell transfusion thresholds for patients with chronic cardiovascular disease:- What is the

    Research recommendation
    Published
    11 December 2015

  15. Reducing antimicrobial resistance:- What interventions, systems and processes are effective and cost effective in reducing antimicrobial resistance without causing harm to patients?

    Recommendation ID NG15/1 Question Reducing antimicrobial resistance:- What interventions, systems and processes are effective and cost

    Research recommendation
    Published
    12 October 2015